Neuphoria Therapeutics (NEUP) Non Operating Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Non Operating Income of $671793.0 for Q1 2026, up 184.37% year-over-year from $236236.6 in Q1 2025, and down 88.59% on a QoQ basis from $5.9 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Non Operating Income data on file, last reported at $671793.0 in Q1 2026.
- Quarterly Non Operating Income rose 184.37% year-over-year to $671793.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 119.42% YoY) and the FY2025 annual result came in at $97032.0, down 95.8% from the prior year.
- Non Operating Income fell to $671793.0 in Q1 2026 per NEUP's latest filing, from $5.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $5.9 million in Q4 2025 and bottomed at -$4.3 million in Q3 2025.
- The 4-year median for Non Operating Income is -$36356.0 (2023), against an average of $425747.1.
- The widest annual swing landed in 2024, when Non Operating Income jumped 6717.58%; it then tumbled 263.02% in 2025.
- Tracing NEUP's Non Operating Income over 4 years: stood at -$36356.0 in 2023, then jumped by 4973.39% to $1.8 million in 2024, then jumped by 232.44% to $5.9 million in 2025, then sank by 88.59% to $671793.0 in 2026.
- Per Business Quant, the three latest NEUP Non Operating Income figures stand at $671793.0 (Q1 2026), $5.9 million (Q4 2025), and -$4.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 671,793.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 671,793.00 |
| Dec 31, 2025 | 5.89 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Jun 30, 2025 | -3.51 Mn |
| Mar 31, 2025 | -796,218.00 |
| Dec 31, 2024 | 1.77 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 401,632.00 |
| Mar 31, 2024 | -367,734.00 |
| Dec 31, 2023 | -36,356.00 |
| Sep 30, 2023 | -39,754.00 |